Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease

Molecular Psychiatry

Volumn 15, Issue 3, 2010, Pages 272-285

  Toledo, E M ^a   Inestrosa, N C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

BSB; Memory flexibility; Oligomers; Thioflavin S; Transgenic; Water maze

Indexed keywords

LITHIUM CHLORIDE; ROSIGLITAZONE; WNT1 PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; EXON; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HISTOCHEMISTRY; IN VIVO STUDY; MEMORY DISORDER; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; BRAIN; DISEASE MODELS, ANIMAL; INFLAMMATION; LITHIUM COMPOUNDS; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PRESENILIN-1; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; WNT PROTEINS;

EID: 77249109792     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2009.72     Document Type: Article

References (77)

1. Salmon D, Bondi M. The Neuropsychology of Alzheimer's Disease. 2nd edn. Raven Press: New York, 1999.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
5. Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Mol Neurodegener 2008; 3: 9.
6. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al. Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
7. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3b facilitates staurosporine-and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000; 275: 7583-7590.
8. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against b-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002; 4: 153-165.
9. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. PNAS 1996; 93: 8455-8459.
10. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. PNAS 2005; 102: 6990-6995.
11. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3b signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27: 1981-1991.
12. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G et al. Activation of Wnt signaling rescues neurodegen-eration and behavioral impairments induced by b-amyloid fibrils. Mol Psychiatry 2003; 8: 195-208.
13. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3a regulates production of Alzheimer's disease amyloid-b peptides. Nature 2003; 423: 435-439.
14. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-b precursor protein processing. Biochemistry 2004; 43: 6899-6908.
15. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997; 1: 235-241.
16. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome proliferator-activated receptor g induces a clearance mechanism for the amyloid-b peptide. J Neurosci 2004; 24: 10908-10917.
17. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor g is expressed in hippocampal neurons and its activation prevents b-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 2005; 304: 91-104.
18. Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F et al. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem 2006; 98: 364-371.
19. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharma-cogenomics J 2006; 6: 246-254.
20. Pedersen WA, Flynn ER. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2004; 17: 500-506.
21. Brodbeck J, Balestra ME, Saunders AM, Roses AD, Mahley RW, Huang Y. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. PNAS 2008; 105: 1343-1346.
22. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA et al. Mutant presenilins specifically elevate the levels of the 42 residue b-amyloid peptide in vivo: evidence for augmentation of a 42-specific g secretase. Hum Mol Genet 2004; 13: 159-170.
23. Chacon MA, Reyes AE, Inestrosa NC. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. J Neurochem 2003; 87: 195-204.
24. Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yevenes LF, Inestrosa NC et al. STI571 prevents apoptosis, tau phosphoryla-tion and behavioural impairments induced by Alzheimer's b-amyloid deposits. Brain 2008; 131: 2425-2442.
25. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ et al. A learning deficit related to age and b-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408: 975-979.
26. Reyes AE, Chacon MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-Ab complexes are more toxic than Ab fibrils in rat hippocampus: effect on rat b-amyloid aggregation, laminin expression, reactive astrocytosis, and neuro-nal cell loss. Am J Pathol 2004; 164: 2163-2174.
27. Chacon MA, Barria MI, Soto C, Inestrosa NC. b-Sheet breaker peptide prevents Ab-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry 2004; 9: 953-961.
28. Schmidt ML, Schuck T, Sheridan S, Kung M-P, Kung H, Zhuang Z-P et al. The fluorescent congo red derivative, (Trans, Trans)-1-Bromo-2,5-Bis-(3- Hydroxycarbonyl-4-Hydroxy)Styrylbenzene (BSB), labels diverse b-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 2001; 159: 937-943.
29. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP et al. Congo red and thioflavin-T analogs detect Ab oligomers. J Neurochem 2008; 104: 457-468.
30. Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM et al. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 2004; 41: 625-638.
31. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes b-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 2004; 297: 186-196.
32. Varela-Nallar L, Toledo EM, Larrondo LF, Cabral ALB, Martins VR, Inestrosa NC. Induction of cellular prion protein gene expression by copper in neurons. Am J Physiol Cell Physiol 2006; 290: C271-C281.
33. Farias GG, Alfaro IE, Cerpa W, Grabowski CP, Godoy JA, Bonansco C et al. Wnt-5a/JNK signaling promotes the clustering of PSD-95 in hippocampal neurons. J Biol Chem 2009; 284: 15857-15866.
34. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL et al. Cyclohexanehexol inhibitors of Ab aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12: 801-808.
35. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006; 24: 516-524. (Pubitemid 44716680)
36. Marcus WL. Lithium: a review of its pharmacokinetics, health effects, and toxicology. J Environ Pathol Toxicol Oncol 1994; 13: 73-79.
37. Schou M. Pharmacology and toxicology of lithium. Annu Rev Pharmacol Toxicol 1976; 16: 231-243.
38. Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V et al. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. PNAS 2006; 103: 3410-3415.
39. Morris RG. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1453-1465.
40. Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M. Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. IUBMB Life 2007; 59: 316-321.
41. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL et al. Synaptic targeting by Alzheimer's-related amyloid b oligomers. J Neurosci 2004; 24: 10191-10200.
42. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
43. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. Ab oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
44. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Ab and synaptic dysfunction. Neuron 2003; 39: 409-421.
45. Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, Ferrer I et al. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex 2009; 19: 586-592.
46. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489.
47. Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC. Protein kinase C inhibits amyloid b peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 2002; 16: 1982-1984.
48. Quintanilla RA, Munoz FJ, Metcalfe MJ, Hitschfeld M, Olivares G, Godoy JA et al. Trolox and 17b-estradiol protect against amyloid b-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J Biol Chem 2005; 280: 11615-11625.
49. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from b-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004; 17: 337-348.
50. Dinamarca MC, Colombres M, Cerpa W, Bonansco C, Inestrosa NC. b-Amyloid oligomers affect the structure and function of the postsynaptic region: role of the Wnt signaling pathway. Neurode-gener Dis 2008; 5: 149-152.
51. Williams RS, Harwood AJ. Lithium therapy and signal transduc-tion. Trends Pharmacol Sci 2000; 21: 61-64.
52. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegen-erative diseases. J Pharmacol Sci 2005; 99: 307-321.
53. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
54. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharma-cology 2005; 30: 1223-1237.
55. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 1997; 411: 183-188.
56. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003; 5: 301-308.
57. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not Ab or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007; 170: 1669-1675.
58. Landreth G. PPARg agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol 2006; 199: 245-248.
59. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G et al. Peroxisome proliferator-activated receptor g up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-37015.
60. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C et al. Acute treatment with the PPARg agonist pioglitazone and ibuprofen reduces glial inflammation and Ab1-42 levels in APPV717I transgenic mice. Brain 2005; 128(Pt 6): 1442-1453.
61. Lee JS, Ishimoto A, Yanagawa S. Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway. J Biol Chem 1999; 274: 21464-21470.
62. Schulte G, Bryja V, Rawal N, Castelo-Branco G, Sousa KM, Arenas E. Purified Wnt-5a increases differentiation of midbrain dopami-nergic cells and dishevelled phosphorylation. J Neurochem 2005; 92: 1550-1553.
63. Toledo EM, Colombres M, Inestrosa NC. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 2008; 86: 281-296.
64. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Ab peptide: the many roads to perdition. Neuron 2004; 43: 605-608.
65. Leissring MA. The AbCs of Ab-cleaving proteases. J Biol Chem 2008; 283: 29645-29649.
66. Yin K-J, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-b peptide catabolism. J Neurosci 2006; 26: 10939-10948.
67. Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49: 489-502.
68. Wu B, Crampton SP, Hughes CCW. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007; 26: 227-239.
69. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P et al. The metalloproteinase matrilysin is a target of b-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-2891.
70. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. b-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-1038.
71. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME et al. Degradation of the Alzheimer disease amyloid b-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006; 281: 17670-17680.
72. Schechter R, Yen SH, Terry RD. Fibrous astrocytes in senile dementia of the Alzheimer type. J Neuropathol Exp Neurol 1981; 40: 95-101.
73. Kish SJ, Morito CL, Hornykiewicz O. Brain glutathione peroxidase in neurodegenerative disorders. Neurochem Pathol 1986; 4: 23-28.
74. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM et al. b-Amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 2005; 20: 187-198.
75. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P et al. Soluble b-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 2005; 25: 11061-11070.
76. Cerpa W, Godoy JA, Alfaro I, Farias GG, Metcalfe MJ, Fuentealba R et al. WNT-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem 2008; 283: 5918-5927.
77. He P, Shen Y. Interruption of b-catenin signaling reduces neurogen-esis in Alzheimer's disease. J Neurosci 2009; 29: 6545-6557.